Capital News

Transthyretin Amyloidosis (ATTR) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Transthyretin Amyloidosis (ATTR) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

March 20
19:38 2020
Transthyretin Amyloidosis (ATTR)  Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

(Albany, US) DelveInsight has launched a new report on Transthyretin Amyloidosis (ATTR) Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Transthyretin Amyloidosis (ATTR) Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Transthyretin Amyloidosis (ATTR), historical and forecasted epidemiology as well as the Transthyretin Amyloidosis (ATTR) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Transthyretin amyloidosis (ATTR) is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. ATTR is often related to manifestations, such as polyneuropathy, cardiomyopathy, and often a mixture of these. ATTR can be subclassified as wild-type (wt) or hereditary, and the latter is then further subdivided into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). Transthyretin Amyloidosis runs in the families when genes get passed from the parents to their children. Individuals with ATTR sport a genetic mutation that prevents TTR protein, which is made in the liver, from performing its normal function. Instead, TTR misfolds and accumulates as amyloid deposits in the body—in the heart, nerves, and GI tract, as well as other organs causing various symptoms. There are variations in the symptoms of ATTR that depend on the TTR genetic variant that is involved and the organ that is affected.

 

Request for:- Transthyretin Amyloidosis (ATTR) free sample page

 

Transthyretin Amyloidosis (ATTR) Epidemiology

The Transthyretin Amyloidosis (ATTR) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken

Report key facts:- 

1. In 2017, the total diagnosed prevalent population of Hereditary ATTR amyloidosis (hATTR) and Transthyretin Amyloidosis wild-type (ATTRwt) in 7MM was 11,330 and 8,014, respectively.

2. According to DelveInsight’s analysis, in 2017, there were 5,241 cases of Familial Amyloid Polyneuropathy and  6,089 cases of Familial Amyloid Cardiomyopathy in the 7MM.

3. In 2017, the total diagnosed prevalent population of ATTR in 7MM was 19,344.

 

Report Key Benefits:-  

1. Transthyretin Amyloidosis (ATTR) market report covers a descriptive overview and comprehensive insight of the Transthyretin Amyloidosis (ATTR) epidemiology Transthyretin Amyloidosis (ATTR) market in the 7MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Transthyretin Amyloidosis (ATTR) market report provides insights on the current and emerging therapies. 

3. Transthyretin Amyloidosis (ATTR) market report offers a global historical and forecasted market covering drug outreach in 7MM.

4. Transthyretin Amyloidosis (ATTR) market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Transthyretin Amyloidosis (ATTR) market.

 

“According to DelveInsight’s analysis, hereditary cases of ATTR are more prominent in comparison to wild-type cases”

Key companies working on Transthyretin Amyloidosis (ATTR) are given below-

1. Pfizer Pharma Co.  

2. Alnylam Pharma Co. 

3. Akcea/Ionis Pharma Co. 

Name of drugs covered are given below:- 

1. Vyndaqel

2. Vyndamax

3. Onpattro

 

Table of Content

1. Key Insights

2. Transthyretin Amyloidosis (ATTR): Overview at a Glance

3. Transthyretin-Related Amyloidosis: Disease Background and Overview

4. Epidemiology and Patient Population

5. Epidemiology by Country

6. 7MM Diagnosed Prevalent and Surgery Cases of ATTR Related Carpal Tunnel Syndrome

7. Current Treatment and Medical Practices

8. Unmet Needs

9. Marketed Drugs

10. Emerging Therapies

11. Transthyretin Amyloidosis: Market Analysis

12. Transthyretin Amyloidosis: 7 Major Market Outlook

13. Market Outlook by Country

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

17.1. Sources Used

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight 

 

Related Report:- 

1. Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade’s Disease) – Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/